-
1Academic Journal
-
2
المؤلفون: Ozkan Kanat, Ozlem Saraydaroglu, Turkkan Evrensel, Ömer Fatih Ölmez, Erdem Cubukcu, Unsal Akcali, Ender Kurt, Osman Manavoglu
المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı., Çubukçu, Erdem, Ölmez, Ömer Fatih, Saraydaroǧlu, Özlem, Akçalı, Ünsal, Kanat, Özkan, Kurt, Ender, Evrensel, Türkkan, Manavoǧlu, Osman, AAJ-1027-2021, AAH-9701-2021
المصدر: Clinical and Translational Oncology. 13:826-830
مصطلحات موضوعية: Male, Oncology, Cancer Research, Pathology, Lung Neoplasms, Resistance, Protein function, Cancer staging, Gene, Carboplatin, Carcinoma, Non-Small-Cell Lung, Medicine, Overall survival, Disease free survival, Etoposide, Excision Repair Cross-Complementing 1, General Medicine, Middle Aged, Excision repair cross complementing protein 1, Prognosis, Immunohistochemistry, DNA-Binding Proteins, Lung non small cell cancer, Chemotherapy, Adjuvant, Lung carcinogenesis, Female, Non small cell, Protein determination, Human, medicine.drug, Adult, medicine.medical_specialty, Paclitaxel, Histopathology, Antineoplastic Agents, Article, Disease-Free Survival, Messenger-RNA, Disease association, Survival probability, Internal medicine, Dna-repair, Chemotherapy, Humans, Human tissue, Lung cancer, DNA Repair, Value of Repair, Ribonucleotide Reductases, Aged, Molecular pathology, Cisplatin, Intermethod comparison, business.industry, Protein localization, Follow up, Endonucleases, medicine.disease, Gemcitabine, Cancer survival, respiratory tract diseases, Outcome assessment, Progression free survival, Protein expression, Molecular Profile, Therapy, ERCC1, Excision repair cross-complementing 1, Prediction, business, Non-small-cell lung cancer, Controlled study, Biomarkers
-
3
المصدر: Известия вузов. Инвестиции. Строительство. Недвижимость.
وصف الملف: text/html